CHICAGO, July 11, 2021 /PRNewswire/ — Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer’s dementia. This treatment offers a marginal but potentially meaningful slowing of decline for this subpopulation of individuals with Alzheimer’s disease, a terminal disease with no survivors. Though approved, access to the treatment is at risk of being impeded by significant barriers which may further deepen issues of health equity.
To proactively and definitively address several of these barriers to appropriate and equitable access, the Alzheimer’s Association supports the Centers for Medicare & Medicaid Services (CMS) undertaking a national coverage analysis culminating in a National Coverage Determination (NCD), that provides coverage to those specified in the Food and Drug Administration’s revised label. Among other benefits, an NCD can help…
